AR106750A1 - HIV MATURATION INHIBITOR FORMULATIONS - Google Patents
HIV MATURATION INHIBITOR FORMULATIONSInfo
- Publication number
- AR106750A1 AR106750A1 ARP160103539A ARP160103539A AR106750A1 AR 106750 A1 AR106750 A1 AR 106750A1 AR P160103539 A ARP160103539 A AR P160103539A AR P160103539 A ARP160103539 A AR P160103539A AR 106750 A1 AR106750 A1 AR 106750A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor compound
- formulation
- maturation inhibitor
- drugs useful
- useful against
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una formulación de tres fármacos de fármacos antirretrovirales útiles frente al VIH, que comprende a) un compuesto inhibidor de la maduración; b) un compuesto inhibidor de la integrasa; y c) un compuesto inhibidor de la proteasa. Reivindicación 5: Una formulación de tres fármacos de fármacos antirretrovirales útiles frente a VIH, que comprende: a) el compuesto inhibidor de la maduración seleccionado del grupo de fórmula (1) y (2); b) dolutegravir; y c) atazanavir. Reivindicación 14: Una formulación de tres fármacos de fármacos antirretrovirales útil frente a VIH, que comprende: a) el compuesto inhibidor de la maduración de fórmula (1); b) atazanavir; y c) un compuesto NRTI. Reivindicación 15: Una formulación de tres fármacos de fármacos antirretrovirales útil frente a VIH, que comprende: a) el compuesto inhibidor de la maduración de fórmula (1); b) atazanavir; y c) tenofovir. Reivindicación 20: Un procedimiento de tratamiento de infección por VIH, que comprende la administración a un paciente que necesita la formulación como se reivindica en la reivindicación 5.Claim 1: A formulation of three antiretroviral drug drugs useful against HIV, comprising a) a maturation inhibitor compound; b) an integrase inhibitor compound; and c) a protease inhibitor compound. Claim 5: A formulation of three antiretroviral drug drugs useful against HIV, comprising: a) the maturation inhibitor compound selected from the group of formula (1) and (2); b) dolutegravir; and c) atazanavir. Claim 14: A formulation of three antiretroviral drug drugs useful against HIV, comprising: a) the maturation inhibitor compound of formula (1); b) atazanavir; and c) an NRTI compound. Claim 15: A formulation of three antiretroviral drug drugs useful against HIV, comprising: a) the maturation inhibitor compound of formula (1); b) atazanavir; and c) tenofovir. Claim 20: A method of treating HIV infection, comprising administration to a patient in need of the formulation as claimed in claim 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257871P | 2015-11-20 | 2015-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106750A1 true AR106750A1 (en) | 2018-02-14 |
Family
ID=61247568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103539A AR106750A1 (en) | 2015-11-20 | 2016-11-18 | HIV MATURATION INHIBITOR FORMULATIONS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR106750A1 (en) |
-
2016
- 2016-11-18 AR ARP160103539A patent/AR106750A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37710A (en) | INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| CU20170089A7 (en) | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | |
| CL2016000698A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
| NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| CU20150096A7 (en) | AMIDA COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR HIV TREATMENT | |
| CL2015001864A1 (en) | Compounds derived from substituted spiropyrido [1,2-a] pyrazine, as hiv integrase inhibitors; pharmaceutical composition that includes them; and its use for the prophylaxis or treatment of a hiv infection. | |
| UY36212A (en) | TOLL TYPE RECEIVER MODULATORS FOR HIV TREATMENT | |
| NZ733125A (en) | Isoquinoline compounds for the treatment of hiv | |
| PH12020500076A1 (en) | Long-acting formulations | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| DOP2018000035A (en) | ACID DERIVATIVES 5- (N-BENCIL-TETRAHYDROISOQUINOLIN-6-IL) -PIRIDIN-3-IL ACETIC AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| DOP2017000307A (en) | ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARATION OF THE SAME. | |
| CO2021012579A2 (en) | Useful compounds in hiv therapy | |
| CL2017000714A1 (en) | Long-acting pharmaceutical compositions | |
| BR112018002689A2 (en) | compound, useful composition and method for treating HIV infection | |
| EA201890906A1 (en) | DERIVATIVES OF CHINOXALINE AND PYRIDOPYRASINE AS PI3Kβ INHIBITORS | |
| CO2021008962A2 (en) | Active Testosterone Ester Derivatives, Compositions and Uses Thereof | |
| BR112018002678A2 (en) | compound, composition, and method for treating HIV infection | |
| BR112018003181A2 (en) | compound, composition, and method for treating HIV infection | |
| AR106750A1 (en) | HIV MATURATION INHIBITOR FORMULATIONS | |
| BR112018002681A2 (en) | ? compound, composition, and method for treating hiv infection? | |
| BR112018000179A2 (en) | compound, composition, and method for treating HIV infection. | |
| UA109243U (en) | A SOLID MEDICINAL FORM CONTAINING PROTEASE INHIBITOR | |
| WO2016112339A8 (en) | Stable formulations for the oral administration of amphotericin b and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |